The Interventional Tumor Ablation segmentation by modality distinguishes three core technology platforms that collectively shaped a global market valued at USD 1.84 billion in 2023. Radiofrequency ablation dominates with a 42% share, leveraging resistive tissue heating to deliver predictable, cost-effective coagulative necrosis in hepatic and renal lesions; its clinical familiarity and broad probe portfolio translate into the highest procedural volume. Microwave ablation, growing at 9% CAGR, extends ablative margins by 15–20% compared with RF, mitigating heat-sink risk near vasculature and capturing a 28% revenue share. Cryoablation, accounting for 18%, exploits rapid freeze–thaw cycles that yield real-time ice-ball visualization, making it the preferred option for perivascular renal and pulmonary tumors where thermal margin tracking is critical. Irreversible electroporation (IRE) occupies a 7% niche; its non-thermal mechanism spares collagenous scaffolding, enabling ablation adjacent to bile ducts and ureters, albeit at premium pricing. High-intensity focused ultrasound (HIFU), at 5%, delivers extracorporeal therapy for uterine fibroids and pancreatic lesions, eliminating percutaneous access risk but requiring prolonged procedural time. Each modality’s interplay with reimbursement codes and hospital capital budgets defines its attainable serviceable obtainable market within the broader Interventional Tumor Ablation market taxonomy.
